Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Today's bounce may be thanks to another name in the cannabis sector.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Shares of Canadian cannabis company OrganiGram Holdings (OGI +0.04%) jumped as much as 15% Friday. As of 3:10 p.m. EDT, shares remained up 11.9% on the day.
The only company-specific news around OrganiGram came earlier this week when the company surprised investors with news that CEO Greg Engel will be leaving that role immediately and that his interim replacement is the board's chairman, Peter Amirault. Engel will remain as a special advisor to the board of directors during an undefined transition period. No reason was given for the change. But today's jump comes after an analyst gave a Canadian cannabis peer an upgrade to a buy rating.
Image source: Getty Images.
Jefferies analyst Owen Bennett upgraded fellow Canadian cannabis company Tilray (TLRY +0.00%) today with a double bump up to a buy rating. Bennett assigned Tilray a price target representing more than 60% upside in the name.
OrganiGram shares seem to be riding that tailwind today. Part of the reason for the Tilray rating was its leadership in the Canadian market, which Bennett said is poised to accelerate growth. That would be good for other companies besides Tilray, and OrganiGram is one that would also benefit.
Last month, OrganiGram expanded beyond its single facility in New Brunswick with the acquisition of The Edibles & Infusions Corporation, a maker of cannabis-infused products including soft-chew edibles. The acquisition gives OrganiGram a second operating facility and a footprint in Western Canada. That expansion would be timed well if the Canadian market growth accelerates, as the analyst predicts. But investors should focus more on the specific results as OrganiGram integrates the acquisition. Today's analyst call on Tilray isn't a good reason for OrganiGram shares to pop.